Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP301626.RATF1Vli5htSEZOrw876U6_1NwqFcnex2Mh1_BXnBGob8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP301626.RATF1Vli5htSEZOrw876U6_1NwqFcnex2Mh1_BXnBGob8130_assertion type Assertion NP301626.RATF1Vli5htSEZOrw876U6_1NwqFcnex2Mh1_BXnBGob8130_head.
- NP301626.RATF1Vli5htSEZOrw876U6_1NwqFcnex2Mh1_BXnBGob8130_assertion description "[Dysregulation of cyclin-dependent kinase 4 (CDK4) and CDK6 by gain of function or loss of inhibition is common in human cancer, including multiple myeloma, but success in targeting CDK with broad-spectrum inhibitors has been modest.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP301626.RATF1Vli5htSEZOrw876U6_1NwqFcnex2Mh1_BXnBGob8130_provenance.
- NP301626.RATF1Vli5htSEZOrw876U6_1NwqFcnex2Mh1_BXnBGob8130_assertion evidence source_evidence_literature NP301626.RATF1Vli5htSEZOrw876U6_1NwqFcnex2Mh1_BXnBGob8130_provenance.
- NP301626.RATF1Vli5htSEZOrw876U6_1NwqFcnex2Mh1_BXnBGob8130_assertion SIO_000772 22718837 NP301626.RATF1Vli5htSEZOrw876U6_1NwqFcnex2Mh1_BXnBGob8130_provenance.
- NP301626.RATF1Vli5htSEZOrw876U6_1NwqFcnex2Mh1_BXnBGob8130_assertion wasDerivedFrom befree-20150227 NP301626.RATF1Vli5htSEZOrw876U6_1NwqFcnex2Mh1_BXnBGob8130_provenance.
- NP301626.RATF1Vli5htSEZOrw876U6_1NwqFcnex2Mh1_BXnBGob8130_assertion wasGeneratedBy ECO_0000203 NP301626.RATF1Vli5htSEZOrw876U6_1NwqFcnex2Mh1_BXnBGob8130_provenance.